DNTH — Dianthus Therapeutics, Inc. /DE/
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1690585 ·
Last close
$86.82
Market Cap
$4.75B
52W High
$96.50
52W Low
$52.07
ADV30
506,423
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 463,000 | — | -46,533,000 | -40,834,000 | 1,246,884,000 | 627,667,000 | 45,570,000 |
| Dec 2025 | 284,000 | — | -69,541,000 | -64,432,000 | 530,922,000 | 51,087,000 | 37,521,000 |
| Sep 2025 | 396,000 | — | -40,288,000 | -36,765,000 | 577,445,000 | 55,984,000 | 30,991,000 |
| Jun 2025 | 193,000 | — | -34,927,000 | -31,629,000 | 326,076,000 | 13,237,000 | 22,997,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-129,060,000
Investing CF
$-122,833,000
Financing CF
$280,125,000
CapEx
$-213,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.10
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-336,729,000
Inventory
—
Receivables
$52,000
ST Investments
$353,208,000
EBIT TTM
$-177,933,000
Pretax Income TTM
$-162,337,000
Interest Exp TTM
—
Analysts
13
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,336,000
EBITDA
$-191,172,992
Free Cash Flow
$-71,029,624
Enterprise Value
$3,617,640,704
Total Cash
$1,111,259,008
Total Debt
$1,364,000
Shares Out
54,666,233
Trailing EPS
$-4.24
Book Value
$22.01
ROE
-22.7%
ROA
-15.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,036,000 | -177,933,000 | -162,337,000 | 530,922,000 | 37,521,000 | — | -129,060,000 |
| Dec 2024 | 6,235,000 | -101,864,000 | -84,969,000 | 374,008,000 | 21,531,000 | — | -78,180,000 |
| Dec 2023 | 2,826,000 | -48,174,000 | -43,555,000 | 179,405,000 | 10,535,000 | — | -36,861,000 |
| Dec 2022 | 6,417,000 | -29,705,000 | -28,476,000 | 83,110,000 | 9,454,000 | — | -29,070,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.65
Max Pain — expiry 2026-11-20
max pain strike: $70.00 · spot: $86.82 · call oi: 5,410 · put oi: 11Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LGND | LIGAND PHARMACEUTICALS INC | $4.72B | $235.33 | — |
| GIFLF | Grifols SA | $4.70B | $11.12 | — |
| FOLD | AMICUS THERAPEUTICS, INC. | $4.55B | $14.49 | — |
| GIKLY | Grifols SA | $4.48B | $5.30 | — |
| INDV | Indivior Pharmaceuticals, Inc. | $4.47B | $37.81 | — |
News headlines (Yahoo Finance, 1h cache)
Dianthus Therapeutics to Participate in Two Investor Conferences
2026-05-26 20:01 · Yahoo
Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases
2026-05-19 19:00 · Yahoo
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish
2026-05-18 17:33 · Yahoo
Assessing Dianthus Therapeutics (DNTH) Valuation After LBL-047 Autoimmune Focus Partnership And Capital Raise
2026-05-18 16:17 · Yahoo
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally
2026-05-17 18:25 · Yahoo
LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis
2026-05-06 02:57 · Yahoo
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue Estimates
2026-05-05 21:15 · Yahoo
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
2026-05-05 20:01 · Yahoo
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-01 20:30 · Yahoo
Assessing Dianthus Therapeutics (DNTH) Valuation After FDA Trial Shift And Renewed Analyst Optimism
2026-04-27 21:04 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.